PRPO
Precipio, Inc.NASDAQHealthcareAs of 2026-04-09
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.08
P/S
2.07
EV/EBITDA
32.41
DCF Value
$-304.84
FCF Yield
0.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
44.5%
Operating Margin
-5.0%
Net Margin
-1.5%
ROE
-2.8%
ROA
-1.7%
ROIC
-6.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $8.0M | $526.0K | $0.33 |
| FY 2025 | $24.0M | $-363.0K | $-0.23 |
| Q3 2025 | $6.2M | $-79.0K | $-0.05 |
| Q2 2025 | $5.7M | $74.0K | $0.05 |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.20
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.